Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy
The DOI matches its Crossref record; 56 of the 56 references it cites were found in a registry or an index.
Abstract
Solid tumors require blood vessels for growth, and many new cancer therapies are directed against the tumor vasculature. The widely held view is that these antiangiogenic therapies should destroy the tumor vasculature, thereby depriving the tumor of oxygen and nutrients. Here, I review emerging evidence supporting an alternative hypothesis—that certain antiangiogenic agents can also transiently “normalize” the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery. Drugs that induce vascular normalization can alleviate hypoxia and increase the efficacy of conventional therapies if both are carefully scheduled. A better understanding of the molecular and cellular underpinnings of vascular normalization may ultimately lead to more effective therapies not only for cancer but also for diseases with abnormal vasculature, as well as regenerative medicine, in which the goal is to create and maintain a functionally normal vasculature.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, the aberrant vasculature also restricts the access of recruited immune cells and anticancer therapeutics to tumors, resulting in reduced outcomes of cancer treatments.[ 18 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [18]
In the citing paper
“Recently, research groups such as Jain, et al., have used the combination therapy of angiogenesis inhibitors along with chemotherapy [24], where the angiogenesis modulators are used to normalize the vasculature and improve the EPR effect–mediated drug delivery and efficacy of the cancer treatment.”
From Approaches to Improve EPR-Based Drug Delivery for Cancer Therapy and Diagnosis (2023) · cites this paper as [24]
In the citing paper
“Because the tumor vasculature is immature (12) and lacks myogenic and autonomic regulation (5)”
In the citing paper
“Conversely, increased glycolytic rate and low perfusion/oxygenation contribute to intratumoral hypoxia and acidosis, which is alleviated with enhanced perfusion (12).”
In the citing paper
“A rationale for combining anti-VEGF therapy with chemotherapy is that anti-VEGF therapy caused tumor vasculature to normalize resulting in increased drug delivery to tumors [123].”
From Recent Advances in Therapeutic Strategies to Improve Colorectal Cancer Treatment (2024) · cites this paper as [123]
4 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Bevacizumab plus Irinotecan, Fluorouracil, and Leucovorin for Metastatic Colorectal Cancer
Hurwitz, H., Fehrenbacher, L., Novotny, W., Cartwright, T., Hainsworth, J., Heim, W., Berlin, J., Baron, A., Griffing, S., Holmgren, E., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa032691 · Cited by 10,968
Tumor angiogenesis: therapeutic implications
Sherwood, L. M., Parris, E. E., & Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197111182852108 · Cited by 10,187
Angiogenesis in cancer and other diseases
Carmeliet, P., & Jain, R. K. (2000) · Nature · doi:10.1038/35025220 · Cited by 9,070
Self-citationAngiogenesis in health and disease
Carmeliet, P. (2003) · Nature Medicine · doi:10.1038/nm0603-653 · Cited by 4,276
Cancer genes and the pathways they control
Vogelstein, B., & Kinzler, K. W. (2004) · Nature Medicine · doi:10.1038/nm1087 · Cited by 4,249
Yang, J. C., Haworth, L., Sherry, R. M., Hwu, P., Schwartzentruber, D. J., Topalian, S. L., Steinberg, S. M., Chen, H. X., & Rosenberg, S. A. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021491 · Cited by 2,697
Transplacental Carcinogenesis by Stilbestrol
Folkman, J. (1971) · New England Journal of Medicine · doi:10.1056/nejm197108122850711 · Cited by 2,640
Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer
Ferrara, N., Hillan, K. J., Gerber, H.-P., & Novotny, W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1381 · Cited by 2,625
Molecular regulation of vessel maturation
Jain, R. K. (2003) · Nature Medicine · doi:10.1038/nm0603-685 · Cited by 2,529
Self-citation
Research works printed but not linked: 12
- D. J. Hicklin L. M. Ellis J. Clin. Oncol. in press.
- J. Ma et al., Cancer Res.61, 5491 (2001).
- R. K. Jain, in Clinical Oncology, M. Abeloff et al., Eds. (Elsevier, New York, ed. 3, 2004), pp. 153–172.
- R. K. Jain, Clin. Cancer Res.5, 1605 (1999).
- C. G. Lee et al., Cancer Res.60, 5565 (2000).
- A. Kadambi et al., Cancer Res.61, 2404 (2001).
- M. Relf et al., Cancer Res.57, 963 (1997).
- Y. Izumi, L. Xu, E. di Tomaso, D. Fukumura, R. K. Jain, Nature416, 279 (2002).
- P. Perrotte et al., Clin. Cancer Res.5, 257 (1999).
- P. M. Gullino, in Biomedical Thermology, M. Gautherie, E. Albert, Eds. (A. R. Liss, New York, 1982), pp. 1–20.
- L. Flintoft, Nature Rev. Cancer4, 754 (2004).
- G. Griffon-Etienne, Y. Boucher, C. Brekken, H. D. Suit, R. K. Jain, Cancer Res.59, 3776 (1999).
Cited by
Items 501–600 of 1,035
Therapeutic application of anti-angiogenic nanomaterials in cancers
Mukherjee, S., & Patra, C. R. (2016) · Nanoscale · doi:10.1039/c5nr07887c · Cited by 169
The promise and challenges of combination therapies with antibody-drug conjugates in solid tumors
Wei, Q., Li, P., Yang, T., Zhu, J., Sun, L., Zhang, Z., Wang, L., Tian, X., Chen, J., Hu, C., et al. (2024) · Journal of Hematology & Oncology · doi:10.1186/s13045-023-01509-2 · Cited by 167
“Within the blood-tumor barrier microenvironment, blood vessels present in solid tumors are composed of many immature and disorganized vessels, resulting in poor blood flow and hypoxia [89].”
BackgroundD’Angelica, M., Kornprat, P., Gonen, M., Chung, K.-Y., Jarnagin, W. R., DeMatteo, R. P., Fong, Y., Kemeny, N., Blumgart, L. H., & Saltz, L. B. (2007) · Annals of Surgical Oncology · doi:10.1245/s10434-006-9074-0 · Cited by 168
Zhao, X., Wei, Z., Zhao, Z., Miao, Y., Qiu, Y., Yang, W., Jia, X., Liu, Z., & Hou, H. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b16910 · Cited by 168
Microfluidics Enabled Bottom-Up Engineering of 3D Vascularized Tumor for Drug Discovery
Agarwal, P., Wang, H., Sun, M., Xu, J., Zhao, S., Liu, Z., Gooch, K. J., Zhao, Y., Lu, X., & He, X. (2017) · ACS Nano · doi:10.1021/acsnano.7b00824 · Cited by 168
Targeting Vascular Pericytes in Hypoxic Tumors Increases Lung Metastasis via Angiopoietin-2
Keskin, D., Kim, J., Cooke, V. G., Wu, C.-C., Sugimoto, H., Gu, C., De Palma, M., Kalluri, R., & LeBleu, V. S. (2015) · Cell Reports · doi:10.1016/j.celrep.2015.01.035 · Cited by 165
“Our findings further imply that vascular normalization and consequently improved vascular perfusion (Augustin et al., 2009; Carmeliet and Jain, 2011a, 2011b; Jain, 2005; Li et al., 2007; Skuli et al., 2009) may be achieved by PGDFRb+ pericyte targeting concomitant with anti-ANG2 antibody therapy.”
BackgroundWays to Enhance Lymphocyte Trafficking into Tumors and Fitness of Tumor Infiltrating Lymphocytes
Bellone, M., & Calcinotto, A. (2013) · Frontiers in Oncology · doi:10.3389/fonc.2013.00231 · Cited by 167
“In general, anti-VEGF-mediated transient normalization of tumor vessels lasts between few days to a month (29).”
BackgroundA review of mathematical models for the formation of vascular networks
Scianna, M., Bell, C. G., & Preziosi, L. (2013) · Journal of Theoretical Biology · doi:10.1016/j.jtbi.2013.04.037 · Cited by 167
“In fact, counterintuitively, Jain and co-workers [109, 130, 131] have hypothesized that it is important to normalise the vascular network through the restoration of a proper balance of pro-angiogenic and anti-angiogenic factors in order to achieve a better delivery of drugs.”
BackgroundMethodResultInfluentialLessons from multidisciplinary translational trials on anti-angiogenic therapy of cancer
Jain, R. K. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2346 · Cited by 165
“This abnormality impedes the delivery of drugs to tumours and creates an abnormal tumour microenvironmen”
BackgroundSelf-citationMattox, A. K., Douville, C., Wang, Y., Popoli, M., Ptak, J., Silliman, N., Dobbyn, L., Schaefer, J., Lu, S., Pearlman, A. H., et al. (2023) · Cancer Discovery · doi:10.1158/2159-8290.cd-21-1252 · Cited by 165
Stromal Endothelial Cells Directly Influence Cancer Progression
Franses, J. W., Baker, A. B., Chitalia, V. C., & Edelman, E. R. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3001542 · Cited by 166
“More recently, the leakiness of tumor blood vessels has been indicted as contributing directly to tumor growth andmetastasis by increasing tumor interstitial pressure (for example, facilitating efflux of cancer cells) and by creating foci of hypoxia and acidosis (3).”
BackgroundEetezadi, S., Ekdawi, S. N., & Allen, C. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2014.10.001 · Cited by 166
Zhou, Y., Ren, X., Hou, Z., Wang, N., Jiang, Y., & Luan, Y. (2021) · Nanoscale Horizons · doi:10.1039/d0nh00480d · Cited by 165
Dawidczyk, C. M., Russell, L. M., & Searson, P. C. (2014) · Frontiers in Chemistry · doi:10.3389/fchem.2014.00069 · Cited by 164
EGFR, HER2 and VEGF Pathways: Validated Targets for Cancer Treatment
Press, M. F., & Lenz, H.-J. (2007) · Drugs · doi:10.2165/00003495-200767140-00006 · Cited by 163
The Impact of the Immune System on Tumor: Angiogenesis and Vascular Remodeling
Stockmann, C., Schadendorf, D., Klose, R., & Helfrich, I. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00069 · Cited by 163
Biomaterials for Craniofacial Bone Engineering
Tevlin, R., McArdle, A., Atashroo, D., Walmsley, G. G., Senarath-Yapa, K., Zielins, E. R., Paik, K. J., Longaker, M. T., & Wan, D. C. (2014) · Journal of Dental Research · doi:10.1177/0022034514547271 · Cited by 164
“Furthermore, addition of multiple GFs, which complement one other temporally and spatially, should be considered (Jain, 2005; Rouwkema et al., 2008).”
BackgroundCascone, T., Herynk, M. H., Xu, L., Du, Z., Kadara, H., Nilsson, M. B., Oborn, C. J., Park, Y.-Y., Erez, B., Jacoby, J. J., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci42405 · Cited by 164
Bevacizumab Has Differential and Dose-Dependent Effects on Glioma Blood Vessels and Tumor Cells
von Baumgarten, L., Brucker, D., Tirniceru, A., Kienast, Y., Grau, S., Burgold, S., Herms, J., & Winkler, F. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-1868 · Cited by 163
“This could explain the positive synergistic effects of VEGF-targeted therapies when used in a multimodal approach (26).”
BackgroundInfluentialGuo, S., Lin, C. M., Xu, Z., Miao, L., Wang, Y., & Huang, L. (2014) · ACS Nano · doi:10.1021/nn5010815 · Cited by 164
“Therefore, antiangiogenic imbalances in the tumor results in tumor vasculature normalization and thus improves NP delivery and accumulation in the tumor.(48) Combination of Figure 7.”
BackgroundYang, X., Zhang, Y., Hosaka, K., Andersson, P., Wang, J., Tholander, F., Cao, Z., Morikawa, H., Tegnér, J., Yang, Y., et al. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1503500112 · Cited by 161
“Paradoxically, anti–VEGF-A drugs such as bevacizumab also have been claimed to induce normalized vasculatures with reduced vascular permeability (28, 32).”
BackgroundWang, D., Xu, Z., Yu, H., Chen, X., Feng, B., Cui, Z., Lin, B., Yin, Q., Zhang, Z., Chen, C., et al. (2014) · Biomaterials · doi:10.1016/j.biomaterials.2014.05.094 · Cited by 163
“The intratumoral blood vessels recruited by tumor angiogenesis not only supply sufficient nutrient and oxygen for the proliferation of cancer cells, but also promote their spreading from the primary site to a secondary tumor follow the direction of blood flow [7].”
BackgroundHelfrich, I., Scheffrahn, I., Bartling, S., Weis, J., von Felbert, V., Middleton, M., Kato, M., Ergün, S., Augustin, H. G., & Schadendorf, D. (2013) · Journal of Experimental Medicine · doi:10.1084/jem.200918462104c · Cited by 163
Breakthroughs in Hepatocellular Carcinoma Therapies
Singal, A. G., Kudo, M., & Bruix, J. (2023) · Clinical Gastroenterology and Hepatology · doi:10.1016/j.cgh.2023.01.039 · Cited by 162
Morphologic Instability and Cancer Invasion
Cristini, V., Frieboes, H. B., Gatenby, R., Caserta, S., Ferrari, M., & Sinek, J. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-0852 · Cited by 163
“This idea was first introduced by Jain and coworkers [50,51] with the”
BackgroundMethodWen, P. Y., Yung, W. K. A., Lamborn, K. R., Norden, A. D., Cloughesy, T. F., Abrey, L. E., Fine, H. A., Chang, S. M., Robins, H. I., Fink, K., et al. (2009) · Neuro-Oncology · doi:10.1215/15228517-2009-010 · Cited by 162
Self-citationImaging angiogenesis and the microenvironment
FUKUMURA, D., & JAIN, R. K. (2008) · APMIS · doi:10.1111/j.1600-0463.2008.01148.x · Cited by 162
“As discussed earlier, excess production of pro-angiogenic molecules and/or diminished production of anti-angiogenic molecules may cause the abnormalities in vessels and microenvironment in tumors resulting in insufficient drug delivery and therapeutic efficacy (13).”
BackgroundSelf-citationHuang, R. Y., Neagu, M. R., Reardon, D. A., & Wen, P. Y. (2015) · Frontiers in Neurology · doi:10.3389/fneur.2015.00033 · Cited by 159
“These observations support the theory of “vascular normalization” as the mechanism of action (167), and a “vascular normalization index” (VNI) combining Ktrans and circulating collagen IV were subsequently proposed as a marker to predict survival (165).”
MethodFranco, M., Man, S., Chen, L., Emmenegger, U., Shaked, Y., Cheung, A. M., Brown, A. S., Hicklin, D. J., Foster, F. S., & Kerbel, R. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3295 · Cited by 162
“Several theories have been put forward to explain the aforementioned paradoxical findings, including the following: (a) antiangiogenic drug-induced drops in the high interstitial fluid pressures within tumors and subsequent increased facilitation of intratumoral delivery of chemotherapy as well as transient ‘‘normaliz…”
BackgroundInfluentialPericytes: gatekeepers in tumour cell metastasis?
Gerhardt, H., & Semb, H. (2008) · Journal of Molecular Medicine · doi:10.1007/s00109-007-0258-2 · Cited by 161
“Part of the increased efficacy of the combined approach may be due to initial tumour vascular normalization reducing intra-tumoural pressure and improving drug delivery for chemotherapy [65].”
BackgroundAu, J. L.-S., Yeung, B. Z., Wientjes, M. G., Lu, Z., & Wientjes, M. G. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.12.002 · Cited by 161
Zhu, A. X., Holalkere, N. S., Muzikansky, A., Horgan, K., & Sahani, D. V. (2008) · The Oncologist · doi:10.1634/theoncologist.2007-0174 · Cited by 161
“Preclinical studies have shown that inhibition of VEGF produces a number of effects on the tumor vasculature, including vessel regression [14], vessel normalization [15, 16 ], and inhibition of neovascularization [17, 18].”
BackgroundMechanisms of Cancer Cell Metastasis to the Bone: A Multistep Process
Patel, L. R., Camacho, D. F., Shiozawa, Y., Pienta, K. J., & Taichman, R. S. (2011) · Future Oncology · doi:10.2217/fon.11.112 · Cited by 161
Xu, L., Duda, D. G., di Tomaso, E., Ancukiewicz, M., Chung, D. C., Lauwers, G. Y., Samuel, R., Shellito, P., Czito, B. G., Lin, P.-C., et al. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-2099 · Cited by 161
“In addition, bevacizumab significantly decreased the expression of Ang1 and Ang2—key factors in angiogenesis and vascular normalization (12)—in cancer cells and lowered Ang1 in TAMs at day 12 (P < 0.”
BackgroundSelf-citationEpigenetics in renal cell cancer: mechanisms and clinical applications
Joosten, S. C., Smits, K. M., Aarts, M. J., Melotte, V., Koch, A., Tjan-Heijnen, V. C., & van Engeland, M. (2018) · Nature Reviews Urology · doi:10.1038/s41585-018-0023-z · Cited by 161
Mougel, A., Terme, M., & Tanchot, C. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00467 · Cited by 161
“Besides the importance of the timing of administration, the dose of antiangiogenic treatment is a key factor for vessel normalization in the tumor (47, 49).”
Kudo, M. (2019) · Liver Cancer · doi:10.1159/000502905 · Cited by 160
Engineering of a Biomimetic Pericyte-Covered 3D Microvascular Network
Kim, J., Chung, M., Kim, S., Jo, D. H., Kim, J. H., & Jeon, N. L. (2015) · PLOS ONE · doi:10.1371/journal.pone.0133880 · Cited by 160
Xu, Y., Li, Q., Li, X.-Y., Yang, Q.-Y., Xu, W.-W., & Liu, G.-L. (2012) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/1756-9966-31-16 · Cited by 160
“Moreover, single-agent use of antiangiogenesis appears to be insufficient to improve patient survival [4].”
BackgroundThe Mechanics of Single Cell and Collective Migration of Tumor Cells
Lintz, M., Muñoz, A., & Reinhart-King, C. A. (2017) · Journal of Biomechanical Engineering · doi:10.1115/1.4035121 · Cited by 160
“In vivo, collections of tumor cells outgrow, depositing matrix, realigning the matrix fibers, and excreting growth factors to cause mechanical stress and enhanced cellular proliferation [47,153,154].”
BackgroundWang, P., Li, X., Yao, C., Wang, W., Zhao, M., El-Toni, A. M., & Zhang, F. (2017) · Biomaterials · doi:10.1016/j.biomaterials.2017.02.017 · Cited by 160
Kudo, M., Aoki, T., Ueshima, K., Tsuchiya, K., Morita, M., Chishina, H., Takita, M., Hagiwara, S., Minami, Y., Ida, H., et al. (2023) · Liver Cancer · doi:10.1159/000529574 · Cited by 158
“This is because upfront lenvatinib normalizes abnormal vessel, microvessel density, vascular permeability, and drug delivery [62 – 64] resulting in improving TACE ef fi cacy.”
BackgroundAnti‐angiogenic drugs: from bench to clinical trials
Quesada, A. R., Muñoz‐Chápuli, R., & Medina, M. A. (2006) · Medicinal Research Reviews · doi:10.1002/med.20059 · Cited by 159
“In this way, certain anti-angiogenic agents could transiently ‘‘normalize’’ the abnormal structure and function of tumor vasculature to make it more efficient for oxygen and drug delivery.(421) This mechanism might contribute to the frequently observed potentiation of conventional therapies by anti-angiogenic agents.”
Interstitial Fluid Flow and Drug Delivery in Vascularized Tumors: A Computational Model
Welter, M., & Rieger, H. (2013) · PLoS ONE · doi:10.1371/journal.pone.0070395 · Cited by 158
“A currently frequently discussed alternative is to improve the efficacy of drugs by turning the ill-formed tumor vasculature normal again [52] by pharmacological means during or before a conventional therapy.”
A tumor cord model for Doxorubicin delivery and dose optimization in solid tumors
Eikenberry, S. (2009) · Theoretical Biology and Medical Modelling · doi:10.1186/1742-4682-6-16 · Cited by 157
Elusive Identities and Overlapping Phenotypes of Proangiogenic Myeloid Cells in Tumors
Coffelt, S. B., Lewis, C. E., Naldini, L., Brown, J. M., Ferrara, N., & Palma, M. D. (2010) · American Journal Of Pathology · doi:10.2353/ajpath.2010.090786 · Cited by 175
Suicide genes for cancer therapy
Portsmouth, D., Hlavatý, J., & Renner, M. (2007) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2006.12.001 · Cited by 184
Pore, N., Gupta, A. K., Cerniglia, G. J., Jiang, Z., Bernhard, E. J., Evans, S. M., Koch, C. J., Hahn, S. M., & Maity, A. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1239 · Cited by 157
“It has been suggested that anti-VEGF therapy may decrease interstitial fluid pressure, leading to improved tumor vessels, or that antiangiogenic therapy ‘‘normalizes’’ remaining tumor vessels, leading to vasculature that can more efficiently oxygenate tissues oxygenation (43, 44).”
BackgroundSun, Y., Chen, W., Torphy, R. J., Yao, S., Zhu, G., Lin, R., Lugano, R., Miller, E. N., Fujiwara, Y., Bian, L., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abc8922 · Cited by 174
“Distinct from the inhibition of angiogenesis, vascular normalization promotes the formation of a functional vascular network in tumors, reverses hypoxia and increases vascular perfusion (13, 14), and enhances immune cell infiltration within tumors (15).”
BackgroundBaker, G. J., Yadav, V. N., Motsch, S., Koschmann, C. J., Calinescu, A., Mineharu, Y., Camelo-Piragua, S. I., Orringer, D. A., Bannykh, S., Nichols, W. S., et al. (2014) · Neoplasia · doi:10.1016/j.neo.2014.06.003 · Cited by 176
“VEGF inhibitors, such as bevacizumab, are therefore thought to improve quality of life by stabilizing normal brain microvessel structure and reducing brain edema [32,33].”
BackgroundWaite, C. L., & Roth, C. M. (2012) · Critical Reviews in Biomedical Engineering · doi:10.1615/critrevbiomedeng.v40.i1.20 · Cited by 156
Antiangiogenic Therapy for Glioblastoma: Current Status and Future Prospects
Batchelor, T. T., Reardon, D. A., de Groot, J., Wick, W., & Weller, M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0834 · Cited by 165
Tumor angiogenesis—characteristics of tumor endothelial cells
Hida, K., Maishi, N., Torii, C., & Hida, Y. (2016) · International Journal of Clinical Oncology · doi:10.1007/s10147-016-0957-1 · Cited by 170
Heralding a new paradigm in 3D tumor modeling
Fong, E. L. S., Harrington, D. A., Farach-Carson, M. C., & Yu, H. (2016) · Biomaterials · doi:10.1016/j.biomaterials.2016.08.052 · Cited by 155
“vessels either via angiogenesis or vasculogenesis [49].”
Shim, M. K., Yang, S., Sun, I., & Kim, K. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114177 · Cited by 171
Sennino, B., Falcón, B. L., McCauley, D., Le, T., McCauley, T., Kurz, J. C., Haskell, A., Epstein, D. M., & McDonald, D. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0293 · Cited by 154
“normalization of tumor vessels (46), may contribute to the increased efficiency of chemotherapeutics or other agents administered in combination with inhibitors of PDGFR-h signaling (14, 15, 19, 47).”
BackgroundTargeting the Metabolic Microenvironment of Tumors
Bailey, K. M., Wojtkowiak, J. W., Hashim, A. I., & Gillies, R. J. (2012) · Advances in Pharmacology · doi:10.1016/b978-0-12-397927-8.00004-x · Cited by 154
“Vascular normalization, first described by Rakesh K. Jain, is a maturation of existing immature vessels within a tumor when neoangiogenesis is inhibited (Goel et al., 2011; Jain, 2001, 2005).”
BackgroundBrown, J. L., Cao, Z. A., Pinzon-Ortiz, M., Kendrew, J., Reimer, C., Wen, S., Zhou, J. Q., Tabrizi, M., Emery, S., McDermott, B., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0554 · Cited by 154
“Whether the combined effects of Ang2-Tie2 inhibition with cytotoxic therapy are due to normalization of the vascular endothelium in a manner similar to VEGF inhibitors has not been fully determined (43, 44).”
BackgroundRadiation effects on the tumor microenvironment: Implications for nanomedicine delivery
Stapleton, S., Jaffray, D. A., & Milosevic, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.05.021 · Cited by 168
Mechanical Forces in Tumor Angiogenesis
Zanotelli, M. R., & Reinhart-King, C. A. (2018) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-95294-9_6 · Cited by 153
Volumetric chemical imaging by clearing-enhanced stimulated Raman scattering microscopy
Wei, M., Shi, L., Shen, Y., Zhao, Z., Guzman, A., Kaufman, L. J., Wei, L., & Min, W. (2019) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1813044116 · Cited by 161
“6A), which agreed with the abnormal structure of dilated and leaky vasculature in the tumor (60).”
BackgroundShen, J., Rees, T. W., Ji, L., & Chao, H. (2021) · Coordination Chemistry Reviews · doi:10.1016/j.ccr.2021.214016 · Cited by 159
Vascular endothelial growth factor: Biology and therapeutic applications
Ho, Q. T., & Kuo, C. J. (2007) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2007.04.010 · Cited by 182
“It has been proposed that such vascular normalization alters tumor insterstitial pressure, allowing improved delivery of chemotherapy to tumors and thereby facilitating the successful addition of anti-angiogenic therapy to chemotherapy observed in clinical trials (reviewed below) (Jain, 2005).”
BackgroundAdapala, R. K., Thoppil, R. J., Ghosh, K., Cappelli, H. C., Dudley, A. C., Paruchuri, S., Keshamouni, V, Klagsbrun, M., Meszaros, J. G., Chilian, W. M., et al. (2016) · Oncogene · doi:10.1038/onc.2015.83 · Cited by 153
Polymer–drug conjugates as nano-sized medicines
Canal, F., Sanchis, J., & Vicent, M. J. (2011) · Current Opinion in Biotechnology · doi:10.1016/j.copbio.2011.06.003 · Cited by 167
Seiwert, T. Y., Haraf, D. J., Cohen, E. E. W., Stenson, K. M., Witt, M. E., Dekker, A., Kocherginsky, M., Weichselbaum, R. R., Chen, H. X., & Vokes, E. E. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.13.1706 · Cited by 159
“One of several possible explanations is that anti-VEGF therapy leads to “normalization” of blood flow in tumors, decreases interstitial fluid pressures, and increases delivery of oxygen/drugs.(46) Normalization, though, is transient, lasting less than 3-4 days, and may not fully explain the observed complexities in tu…”
Evidence of angiogenic vessels in Alzheimer’s disease
Desai, B. S., Schneider, J. A., Li, J.-L., Carvey, P. M., & Hendey, B. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0226-9 · Cited by 153
“vasculature within the tumor fails to properly deliver macromolecules and oxygen, exacerbating a hypoxic environment (Jain 2005).”
Tumor microenvironment for cancer stem cells
Kise, K., Kinugasa‐Katayama, Y., & Takakura, N. (2015) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2015.08.005 · Cited by 166
Liu, T., Ma, W., Xu, H., Huang, M., Zhang, D., He, Z., Zhang, L., Brem, S., O’Rourke, D. M., Gong, Y., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-05982-z · Cited by 151
Modulating the Tumor Microenvironment to Enhance Tumor Nanomedicine Delivery
Zhang, B., Hu, Y., & Pang, Z. (2017) · Frontiers in Pharmacology · doi:10.3389/fphar.2017.00952 · Cited by 152
“The abnormality in organization and structure of the tumor vasculature leads to heterogeneous blood flow, which directly influences the vascular transport of nanomedicines (Jain, 1994, 2005).”
BackgroundGonzalez–Gronow, M., Cuchacovich, M., Llanos, C., Urzua, C., Gawdi, G., & Pizzo, S. V. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-1721 · Cited by 164
“We also must consider that drugs may not reach deeply beyond the perivascular region due to physical barriers by a stroma and to elevated interstitial pressure, which reduces fluid convection (49).”
BackgroundCrown, J. P., Diéras, V., Staroslawska, E., Yardley, D. A., Bachelot, T., Davidson, N., Wildiers, H., Fasching, P. A., Capitain, O., Ramos, M., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.43.3391 · Cited by 151
Effect of aerobic exercise on tumor physiology in an animal model of human breast cancer
Jones, L. W., Viglianti, B. L., Tashjian, J. A., Kothadia, S. M., Keir, S. T., Freedland, S. J., Potter, M. Q., Jung Moon, E., Schroeder, T., Herndon, J. E., et al. (2010) · Journal of Applied Physiology · doi:10.1152/japplphysiol.00424.2009 · Cited by 149
“The resultant hypoxic microenvironment promotes an aggressive tumor phenotype characterized by invasion and metastasis (17).”
BackgroundPathogenesis and Treatment of Prostate Cancer Bone Metastases: Targeting the Lethal Phenotype
Loberg, R. D., Logothetis, C. J., Keller, E. T., & Pienta, K. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.0841 · Cited by 162
Notch signaling in developmental and tumor angiogenesis
Kofler, N. M., Shawber, C. J., Kangsamaksin, T., Reed, H. O., Galatioto, J., & Kitajewski, J. (2011) · Genes & Cancer · doi:10.1177/1947601911423030 · Cited by 142
Hyperthermia can alter tumor physiology and improve chemo- and radio-therapy efficacy
Dunne, M., Regenold, M., & Allen, C. (2020) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2020.07.007 · Cited by 150
Neuropilins: expression and roles in the epithelium
Wild, J. R. L., Staton, C. A., Chapple, K. S., & Corfe, B. M. (2012) · International Journal of Experimental Pathology · doi:10.1111/j.1365-2613.2012.00810.x · Cited by 174
“This key property of tumour vascular normalization provides a potential therapeutic window to optimize the delivery of cytotoxic drugs and also oxygen to sensitize the tumour for radiotherapy (Jain 2005).”
BackgroundExploring the Tumor Microenvironment with Nanoparticles
Miao, L., & Huang, L. (2015) · Cancer Treatment and Research · doi:10.1007/978-3-319-16555-4_9 · Cited by 144
“Hypoxia renders tumor cells resistant to both cytotoxic drugs and radiation, while also inducing genetic instability and selecting for more malignant tumor cells with potentially metastatic properties [59, 71].”
BackgroundMeeting the Challenge of Targeting Cancer Stem Cells
Turdo, A., Veschi, V., Gaggianesi, M., Chinnici, A., Bianca, P., Todaro, M., & Stassi, G. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00016 · Cited by 162
Cytokine and Chemokine Signals of T‐Cell Exclusion in Tumors
Zhang, Y., Guan, X.-Y., & Jiang, P. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.594609 · Cited by 133
Wang, S., Liu, J., Goh, C. C., Ng, L. G., & Liu, B. (2019) · Advanced Materials · doi:10.1002/adma.201904447 · Cited by 148
Remodeling Tumor Vasculature to Enhance Delivery of Intermediate-Sized Nanoparticles
Jiang, W., Huang, Y., An, Y., & Kim, B. Y. S. (2015) · ACS Nano · doi:10.1021/acsnano.5b02028 · Cited by 148
“drugs often have limited access to tumor regions that are poorly vascularized, necrotic, and hypoxic, leading to their decreased therapeutic efficacy.(13) However,”
Frenkel, V., Etherington, A., Greene, M., Quijano, J., Xie, J., Hunter, F., Dromi, S. A., & Li, K. C. (2006) · Academic Radiology · doi:10.1016/j.acra.2005.08.024 · Cited by 162
Tonra, J. R., Deevi, D. S., Corcoran, E., Li, H., Wang, S., Carrick, F. E., & Hicklin, D. J. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1682 · Cited by 148
Coxon, A., Bready, J., Min, H., Kaufman, S., Leal, J., Yu, D., Lee, T. A., Sun, J.-R., Estrada, J., Bolon, B., et al. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-10-0213 · Cited by 148
Regulators of angiogenesis and strategies for their therapeutic manipulation
Milkiewicz, M., Ispanovic, E., Doyle, J. L., & Haas, T. L. (2005) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2005.10.006 · Cited by 183
“It has been proposed that anti-angiogenic therapies “normalize” the tumor vasculature by reducing vessel tortuosity, decreasing permeability, and pruning unnecessary branches, all of which improve the delivery of chemotherapy agents (Jain, 2005).”
BackgroundCritical Evaluation of Current Treatments in Metastatic Colorectal Cancer
Venook, A. (2005) · The Oncologist · doi:10.1634/theoncologist.10-4-250 · Cited by 148
“FU administered by continuous infusion allows for the delivery of more drug than bolus FU and shifts the dose-limiting toxicity from myelosuppression to hand-foot syndrome, which results in a more favorable toxicity profile [ 2 , 3]. The change in toxicity profile is a result of a higher concentration of FU in the bon…”
BackgroundInfluentialMicroenvironmental regulation of biomacromolecular therapies
Kong, H. J., & Mooney, D. J. (2007) · Nature Reviews Drug Discovery · doi:10.1038/nrd2309 · Cited by 164
Tumor Volume Estimation and Quasi-Continuous Administration for Most Effective Bevacizumab Therapy
Sápi, J., Kovács, L., Drexler, D. A., Kocsis, P., Gajári, D., & Sápi, Z. (2015) · PLoS ONE · doi:10.1371/journal.pone.0142190 · Cited by 156
Antiangiogenic cancer treatment: The great discovery and greater complexity (Review)
Maj, E., Papiernik, D., & Wietrzyk, J. (2016) · International Journal of Oncology · doi:10.3892/ijo.2016.3709 · Cited by 147
Bentzen, S. M., Harari, P. M., & Bernier, J. (2007) · Nature Clinical Practice Oncology · doi:10.1038/ncponc0744 · Cited by 149
“The case for combining radiation with antiangiogenic agents has perhaps seemed less intuitive; however, Jain recently presented the case for antiangiogenic agents inducing a normalization of tumor blood vessels, which in turn reduced tumor hypoxia, creating potential biological cooperation between this class of drugs…”
BackgroundExtracellular Matrix Cues Regulate Mechanosensing and Mechanotransduction of Cancer Cells
Mierke, C. T. (2024) · Cells · doi:10.3390/cells13010096 · Cited by 146
Tumor Vascular Changes Mediated by Inhibition of Oncogenic Signaling
Qayum, N., Muschel, R. J., Im, J. H., Balathasan, L., Koch, C. J., Patel, S., McKenna, W. G., & Bernhard, E. J. (2009) · Cancer Research · doi:10.1158/0008-5472.can-09-0657 · Cited by 146
Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis
Dorrell, M. I., Aguilar, E., Scheppke, L., Barnett, F. H., & Friedlander, M. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0607542104 · Cited by 147
Interstitial Fluid Pressure in Tumors: Therapeutic Barrier and Biomarker of Angiogenesis
Lunt, S. J., Fyles, A., Hill, R. P., & Milosevic, M. (2008) · Future Oncology · doi:10.2217/14796694.4.6.793 · Cited by 145
Hypoxia-Induced Retinal Angiogenesis in Zebrafish as a Model to Study Retinopathy
Cao, R., Jensen, L. D., Söll, I., Hauptmann, G., & Cao, Y. (2008) · PLoS ONE · doi:10.1371/journal.pone.0002748 · Cited by 149
Alexander, S., Weigelin, B., Winkler, F., & Friedl, P. (2013) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2013.07.001 · Cited by 168
Mead, E. J., Maguire, J. J., Kuc, R. E., & Davenport, A. P. (2007) · Endocrinology · doi:10.1210/en.2006-0818 · Cited by 145
“The discovery that the KP are potent vasoconstrictors and are expressed in vasculature makes them possible targets in cancer therapy (39), not only as”
BackgroundKawano, M., Mabuchi, S., Matsumoto, Y., Sasano, T., Takahashi, R., Kuroda, H., Kozasa, K., Hashimoto, K., Isobe, A., Sawada, K., et al. (2015) · Scientific Reports · doi:10.1038/srep18217 · Cited by 145
Lee, Y. J., Shin, K. J., Park, S.-A., Park, K. S., Park, S., Heo, K., Seo, Y.-K., Noh, D.-Y., Ryu, S. H., & Suh, P.-G. (2016) · Oncotarget · doi:10.18632/oncotarget.12286 · Cited by 144
“com/oncotarget proangiogenic and antiangiogenic factors in favor of pro-angiogenesis, applies to almost types of solid tumors [36, 37].”
Background
Metadata
- Authors
- Jain, R. K.
- Affiliations
- Harvard University (US)
- Corresponding author
- Jain, Rakesh K.
- Venue
- Science
- Published
- 2005-01-07
- Volume
- 307
- Issue
- 5706
- Pages
- 58-62
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W2006202974
- Cited by
- 5,527
- References
- 56
- Citations by year
- 2026: 245 · 2025: 212 · 2024: 202 · 2023: 220 · 2022: 236 · 2021: 279 · 2020: 245 · 2019: 236 · 2018: 219 · 2017: 236 · 2016: 252 · 2015: 292 · 2014: 307 · 2013: 361 · 2012: 350
- FWCI
- 19.51
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Physical Sciences › Mathematics › Modeling and Simulation › Mathematical Biology Tumor Growth
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Keywords
- tumor vasculature normalization, anti-angiogenic therapy, tumor hypoxia, tumor oxygenation, drug delivery to tumors, combination cancer therapy, regenerative medicine, vascular function
- MeSH terms
- Animals, Antineoplastic Agents, Antineoplastic Combined Chemotherapy Protocols, Combined Modality Therapy, Humans, Neoplasms, Neovascularization, Pathologic, Signal Transduction, Cell Hypoxia, Angiogenesis Inhibitors, Vascular Endothelial Growth Factor A, Cell Proliferation
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.